Andy Galler Agency Strategist and Growth Officer

Translating Science Into Compelling Narratives

Investigational Experience

KW-6356Parkinson’s Disease
Zandelisib ME-401Myelofibrosis
T-cell lymphomas
KH-4591Macular degeneration
GadopiclenolRadiology (first high-relaxivty macrocyclic contrast agent)
Axalimogene FilolisbacHigh-risk locally advanced cervical cancer
Fuoroestradiol F 18Radioactive diagnostic agent for metastatic breast cancer
ZotiraciclibHigh-grade gliomas
CTB-02Colon and non-small cell lung cancer with pan-KRAS mutations
RigosertibMyelodysplastic syndromes
ON-013105Refractory lymphoma
Tivozanib KHK-4951Wet age-related macular degeneration
Diabetic macular edema
Retinal vein occlusion